patent granted – UF Innovate https://innovate.research.ufl.edu Building business on innovation Tue, 12 Aug 2025 04:18:18 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.4 https://innovate.research.ufl.edu/wp-content/uploads/favicon-blue_1.png patent granted – UF Innovate https://innovate.research.ufl.edu 32 32 Cannabix Technologies Granted Cannabis Drug Detection Device Canadian Patent, Delivers THCBA to US Clinic https://innovate.research.ufl.edu/cannabix-canadian-patent-granted/ Tue, 06 Jul 2021 00:00:00 +0000 https://scaddev1.com/cannabix-canadian-patent-granted/ UF startup Cannabix Technologies Inc., developer of the Cannabix Marijuana Breathalyzer devices for law enforcement and the workplace, announces that the Canadian Intellectual Property Office (CIPO) has granted patent No. 2887841 entitled, “Cannabis Drug Detection Device”. The Company has been pursuing this original patent application since its filing on April 16, 2015. Cannabix Technologies is at the forefront in research and development to create point-of-care breath testing technologies for the detection of ∆9-tetrahydrocannabinol (THC) – the psychoactive component of marijuana that causes impairment.

“Similar to our USPTO patent, the intellectual property protection this THC detection patent covers, gives Cannabix a broad foundation to build upon in view of the formidable insights and technical advancements made in the field of molecular gas analysis at atmospheric pressure that we have developed since this patent was initially filed in 2015. This patent is a useful plank in our IP protection strategy,” said Dr. Raj Attariwala, chief scientific officer at Cannabix Technologies.

Learn more about Cannabix Technologies Granted Cannabis Drug Detection Device Canadian Patent, Delivers THCBA to US Clinic.
Cannabix Technologies Receives Notice of Allowance for Cannabis Drug Detection Device Canadian Patent
Cannabix Technologies Reaches Development Milestone with Marijuana Breathalyzer Devices
Cannabix Technologies Develops Version 3.0 of THC Breath Analyzer Device
]]> Forte & Maghari Patent “Universal Testing Technique” To Detect Counterfeit Chips https://innovate.research.ufl.edu/uf-researchers-patent-fics/ Mon, 03 May 2021 00:00:00 +0000 https://scaddev1.com/uf-researchers-patent-fics/ An article recently published in the Academic Times profiled exciting new technology patented by researchers at the Florida Institute for Cybersecurity (FICS) Research which promises a new way to detect recycled (previously used) and counterfeit electronic parts, especially chips. The technology created by ECE Associate Professor Domenic Forte and ECE Associate Professor Nima Maghari makes supply chains more secure, protects consumer safety and runs at almost zero cost. Compared to current methods of detecting counterfeit hardware (chips, power supplies, electronics components, etc.), the proposed “universal testing technique” can be used on virtually all chips produced by all vendors and can be further improved by applying artificial intelligence algorithms in order to automate detection.

Learn more about Forte & Maghari Patent “Universal Testing Technique” To Detect Counterfeit Chips.
FICS Research Expands Industry Partnerships, Workforce Development
]]> New OxThera/Oxabact US Patent Granted https://innovate.research.ufl.edu/oxthera-us-patent-granted/ Thu, 25 Feb 2021 00:00:00 +0000 https://scaddev1.com/oxthera-us-patent-granted/ UF startup OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces that a new US patent has been granted for its product candidate Oxabact and a method for the treatment or prevention of an oxalate-related disorder, such as hyperoxaluria.

The first formulation of Oxabact was patented and granted back in 1999. Since 2012, the company has developed a new, high-concentrated formulation of Oxabact designed to promote excretion of endogenous oxalate from blood plasma. The new formulation of Oxabact is under final Phase 3 clinical testing in patients with Primary Hyperoxaluria.

“We are happy to announce that our Oxabact product now has another 20 years of patent coverage in the US,” said Matthew Gantz, CEO of OxThera. “Oxabact has great potential to become a new treatment for hyperoxaluria.”

Learn more about New OxThera/Oxabact US Patent Granted.
Related news OxThera Announces Completion of Recruitment in Phase 3 ePHex Study With Oxabact in Patients With Primary Hyperoxaluria. ]]>